Beyond cancer, de novo truncating mutations in ASXL1, ASXL2, and ASXL3 have separately been identified in Bohring–Opitz, Bainbridge–Ropers, and related syndromes [68,69,70]. This evidence concerns the gene ASXL2 and cancer.